Cargando…
The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial
The main aim of this study was to evaluate the ability of serum biomarkers to predict the worsening of retinal neurodysfunction in subjects with type 2 diabetes. For this purpose, we measured selected molecules (N-epsilon-carboxy methyl lysine (CML), laminin P1 (Lam-P1), and asymmetric dimethylargin...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231127/ https://www.ncbi.nlm.nih.gov/pubmed/32344735 http://dx.doi.org/10.3390/jcm9041233 |
_version_ | 1783535119279063040 |
---|---|
author | Hernández, Cristina Porta, Massimo Bandello, Francesco Grauslund, Jakob Harding, Simon P. Aldington, Stephen J. Egan, Catherine Frydkjaer-Olsen, Ulrik García-Arumí, José Gibson, Jonathan Lang, Gabriele E. Lattanzio, Rosangela Massin, Pascale Midena, Edoardo Ponsati, Berta Ribeiro, Luísa Scanlon, Peter Cunha-Vaz, José Simó, Rafael |
author_facet | Hernández, Cristina Porta, Massimo Bandello, Francesco Grauslund, Jakob Harding, Simon P. Aldington, Stephen J. Egan, Catherine Frydkjaer-Olsen, Ulrik García-Arumí, José Gibson, Jonathan Lang, Gabriele E. Lattanzio, Rosangela Massin, Pascale Midena, Edoardo Ponsati, Berta Ribeiro, Luísa Scanlon, Peter Cunha-Vaz, José Simó, Rafael |
author_sort | Hernández, Cristina |
collection | PubMed |
description | The main aim of this study was to evaluate the ability of serum biomarkers to predict the worsening of retinal neurodysfunction in subjects with type 2 diabetes. For this purpose, we measured selected molecules (N-epsilon-carboxy methyl lysine (CML), laminin P1 (Lam-P1), and asymmetric dimethylarginine (ADMA)) in the serum of 341 participants of the EUROCONDOR study at baseline, 24, and 48 weeks. Retinal neurodysfunction was assessed by measuring implicit time (IT) using multifocal electroretinography, and structural changes were examined by spectral domain–optical coherence tomography. The values of IT at baseline were directly correlated with baseline serum concentrations of CML (r = 0.135, p = 0.013). Furthermore, in the placebo group, increase in CML concentration throughout follow-up correlated with the IT (r = 0.20; p = 0.03). Baseline serum levels of CML also correlated with macular retinal thickness (RT) (r = 0.231; p < 0.001). Baseline Lam-P1 levels correlated with the increase of the RT at the end of follow-up in the placebo group (r = 0.22; p = 0.016). We provide evidence that CML may be a biomarker of both retinal neurodysfunction and RT, whereas Lam-P1 was associated with RT only. Therefore, circulating levels of these molecules could provide a complementary tool for monitoring the early changes of diabetic retinopathy (DR). |
format | Online Article Text |
id | pubmed-7231127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72311272020-05-22 The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial Hernández, Cristina Porta, Massimo Bandello, Francesco Grauslund, Jakob Harding, Simon P. Aldington, Stephen J. Egan, Catherine Frydkjaer-Olsen, Ulrik García-Arumí, José Gibson, Jonathan Lang, Gabriele E. Lattanzio, Rosangela Massin, Pascale Midena, Edoardo Ponsati, Berta Ribeiro, Luísa Scanlon, Peter Cunha-Vaz, José Simó, Rafael J Clin Med Article The main aim of this study was to evaluate the ability of serum biomarkers to predict the worsening of retinal neurodysfunction in subjects with type 2 diabetes. For this purpose, we measured selected molecules (N-epsilon-carboxy methyl lysine (CML), laminin P1 (Lam-P1), and asymmetric dimethylarginine (ADMA)) in the serum of 341 participants of the EUROCONDOR study at baseline, 24, and 48 weeks. Retinal neurodysfunction was assessed by measuring implicit time (IT) using multifocal electroretinography, and structural changes were examined by spectral domain–optical coherence tomography. The values of IT at baseline were directly correlated with baseline serum concentrations of CML (r = 0.135, p = 0.013). Furthermore, in the placebo group, increase in CML concentration throughout follow-up correlated with the IT (r = 0.20; p = 0.03). Baseline serum levels of CML also correlated with macular retinal thickness (RT) (r = 0.231; p < 0.001). Baseline Lam-P1 levels correlated with the increase of the RT at the end of follow-up in the placebo group (r = 0.22; p = 0.016). We provide evidence that CML may be a biomarker of both retinal neurodysfunction and RT, whereas Lam-P1 was associated with RT only. Therefore, circulating levels of these molecules could provide a complementary tool for monitoring the early changes of diabetic retinopathy (DR). MDPI 2020-04-24 /pmc/articles/PMC7231127/ /pubmed/32344735 http://dx.doi.org/10.3390/jcm9041233 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hernández, Cristina Porta, Massimo Bandello, Francesco Grauslund, Jakob Harding, Simon P. Aldington, Stephen J. Egan, Catherine Frydkjaer-Olsen, Ulrik García-Arumí, José Gibson, Jonathan Lang, Gabriele E. Lattanzio, Rosangela Massin, Pascale Midena, Edoardo Ponsati, Berta Ribeiro, Luísa Scanlon, Peter Cunha-Vaz, José Simó, Rafael The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial |
title | The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial |
title_full | The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial |
title_fullStr | The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial |
title_full_unstemmed | The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial |
title_short | The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial |
title_sort | usefulness of serum biomarkers in the early stages of diabetic retinopathy: results of the eurocondor clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231127/ https://www.ncbi.nlm.nih.gov/pubmed/32344735 http://dx.doi.org/10.3390/jcm9041233 |
work_keys_str_mv | AT hernandezcristina theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT portamassimo theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT bandellofrancesco theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT grauslundjakob theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT hardingsimonp theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT aldingtonstephenj theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT egancatherine theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT frydkjaerolsenulrik theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT garciaarumijose theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT gibsonjonathan theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT langgabrielee theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT lattanziorosangela theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT massinpascale theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT midenaedoardo theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT ponsatiberta theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT ribeiroluisa theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT scanlonpeter theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT cunhavazjose theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT simorafael theusefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT hernandezcristina usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT portamassimo usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT bandellofrancesco usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT grauslundjakob usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT hardingsimonp usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT aldingtonstephenj usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT egancatherine usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT frydkjaerolsenulrik usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT garciaarumijose usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT gibsonjonathan usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT langgabrielee usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT lattanziorosangela usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT massinpascale usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT midenaedoardo usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT ponsatiberta usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT ribeiroluisa usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT scanlonpeter usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT cunhavazjose usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial AT simorafael usefulnessofserumbiomarkersintheearlystagesofdiabeticretinopathyresultsoftheeurocondorclinicaltrial |